CNS Pharmaceuticals Inc., of Houston, closed the issuance of an additional 318,750 shares of its common stock pursuant to the exercise in full of the underwriters' overallotment option in connection with its IPO. The additional shares were sold at the IPO price of $4 per share, before underwriting discounts and commissions. The Benchmark Co. LLC acted as sole book running manager for the offering.
Heartseed Inc., of Tokyo, raised ¥2.8 billion (US$26 million) in a series B round, bringing its total financial backing to ¥3.8 billion since it was founded in 2015. The round included new investors SBI Investment, JMDC, Gene Techno Science, Nissay Capital and SMBC Capital, and an existing investor, Astellas Venture Management LLC. The company expects to initiate a phase I/II trial with its lead compound, HS-001, for heart failure with reduced ejection fraction in late 2020.
Organogenesis Holdings Inc., of Canton, Mass., priced an underwritten public offering of 9 million shares of its class A common stock at $5 each. The gross proceeds to Organogenesis Holdings from this offering are expected to be $45 million. The company has granted the underwriters a 30-day option to purchase up to 1.35 million more shares. Credit Suisse Securities LLC and SVB Leerink LLC are acting as joint book-running managers, with BTIG LLC and Oppenheimer & Co. Inc. serving as co-managers.